For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $86.07, up 1.68% from its previous closing price of $84.65. In other words, the price has increased by $1.68 from its previous closing price. On the day, 0.72 million shares were traded. PTGX stock price reached its highest trading level at $87.1 during the session, while it also had its lowest trading level at $84.73.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 84.46. For the most recent quarter (mrq), Quick Ratio is recorded 13.05 and its Current Ratio is at 13.05. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $72.
On September 12, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $73.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $72.Citigroup initiated its Buy rating on June 17, 2025, with a $72 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when MOLINA ARTURO MD sold 2,712 shares for $84.77 per share. The transaction valued at 229,896 led to the insider holds 81,180 shares of the business.
Waddill William D. sold 12,000 shares of PTGX for $979,480 on Oct 10 ’25. The Director now owns 5,130 shares after completing the transaction at $81.62 per share. On Oct 10 ’25, another insider, WILLIAM WADDILL, who serves as the Director of the company, bought 12,000 shares for $67.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 5380723200 and an Enterprise Value of 4815355392. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 135.89, and their Forward P/E ratio for the next fiscal year is 112.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.72 while its Price-to-Book (P/B) ratio in mrq is 8.33. Its current Enterprise Value per Revenue stands at 23.016 whereas that against EBITDA is 240.407.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.26, which has changed by 1.0309501 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $93.25, while it has fallen to a 52-week low of $33.70. The 50-Day Moving Average of the stock is 11.22%, while the 200-Day Moving Average is calculated to be 49.77%.
Shares Statistics:
It appears that PTGX traded 1.20M shares on average per day over the past three months and 878310 shares per day over the past ten days. A total of 62.45M shares are outstanding, with a floating share count of 59.08M. Insiders hold about 5.50% of the company’s shares, while institutions hold 110.21% stake in the company. Shares short for PTGX as of 1763078400 were 5582326 with a Short Ratio of 4.65, compared to 1760486400 on 6312028. Therefore, it implies a Short% of Shares Outstanding of 5582326 and a Short% of Float of 10.7.
Earnings Estimates
The market rating of Protagonist Therapeutics Inc (PTGX) is currently shaped by the ongoing analysis conducted by 9.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.43, with high estimates of $0.06 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.26 and -$2.33 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is $0.56, with 9.0 analysts recommending between $5.04 and -$2.36.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $258.9M, while the lowest revenue estimate was $38.58M, resulting in an average revenue estimate of $64.45M. In the same quarter a year ago, actual revenue was $434.43MBased on 11 analysts’ estimates, the company’s revenue will be $270.37M in the next fiscal year. The high estimate is $525M and the low estimate is $20M.
